New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTesamorelin vs Eloralintide

Tesamorelin vs Eloralintide

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone PeptidesFat Loss & Metabolic
Tesamorelin
GLP-1 / Weight Loss Agonists
Eloralintide
Summary
Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
Half-Life
~26 minutes
~7 days (estimated, long-acting design)
Admin Route
SubQ
SubQ
Research
Typical Dose
2 mg
Under investigation in Phase 1/2 trials
Frequency
Once daily
Once weekly
Key Benefits
  • FDA-approved for visceral fat reduction in HIV lipodystrophy
  • Significant reduction in trunk/visceral fat (average 15–20% in trials)
  • Improved triglyceride and lipid profiles
  • Potential cognitive benefits and memory improvement
  • Preserves lean mass while reducing fat
  • Natural pulsatile GH stimulation
  • Once-weekly dosing (vs multiple daily injections for pramlintide)
  • Appetite suppression via central amylin receptor activation
  • Reduction in post-meal glucagon secretion
  • Complementary mechanism to GLP-1 agonists for combination therapy
  • Slows gastric emptying for prolonged satiety
  • Potential additive weight loss when combined with GLP-1 agents
Side Effects
  • Injection site reactions (redness, irritation)
  • Arthralgia and joint pain
  • Peripheral edema
  • Carpal tunnel syndrome
  • +2 more
  • Nausea
  • Vomiting
  • Decreased appetite
  • Injection site reactions
  • +1 more
Stacks With